Financials Molecure S.A.

Equities

MOC

PLONCTH00011

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:41 2024-07-11 am EDT			5-day change	1st Jan Change
13.78 ^PLN	-0.14%		+4.24%	-29.33%

May. 21	Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway	CI
May. 17	Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Valuation

Fiscal Period: December	2019	2022	2023	2024	2025
Capitalization ¹	133.7	200.1	328.3	232	-
Enterprise Value (EV) ¹	102.2	200.1	271.5	180.3	212.2
P/E ratio	-32.6 x	-13.1 x	-17.9 x	-	-9.84 x
Yield	-	-	-	-	-
Capitalization / Revenue	65.7 x	-	247 x	4.4 x	14.3 x
EV / Revenue	50.2 x	-	204 x	3.42 x	13.1 x
EV / EBITDA	-22.3 x	-	-13.4 x	66.8 x	-9.82 x
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Price to Book	1.69 x	-	2.09 x	1.47 x	1.77 x
Nbr of stocks (in thousands)	13,670	14,030	16,836	16,836	-
Reference price ²	9.780	14.26	19.50	13.78	13.78
Announcement Date	3/30/20	3/30/23	5/17/24	-	-

¹PLN in Million²PLN

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2022	2023	2024	2025
Net sales ¹	2.035	-	1.328	52.7	16.2
EBITDA ¹	-4.587	-	-20.26	2.7	-21.6
EBIT ¹	-4.827	-	-22.1	0.8	-23.8
Operating Margin	-237.21%	-	-1,664.3%	1.52%	-146.91%
Earnings before Tax (EBT) ¹	-4.166	-	-18.31	1.3	-23.5
Net income ¹	-4.166	-15.26	-18.31	-0.1	-23.8
Net margin	-204.73%	-	-1,378.52%	-0.19%	-146.91%
EPS ²	-0.3000	-1.090	-1.090	-	-1.400
Free Cash Flow	-	-	-	-	-
FCF margin	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	3/30/20	3/30/23	5/17/24	-	-

¹PLN in Million²PLN

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S1	2022 Q3	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1
Net sales ¹	-	0.227	0.981	0.0229	0.2368	0.0767	0.0284
EBITDA ¹	-	-2.856	-3.814	-5.185	-4.684	-6.573	-6.525
EBIT ¹	-	-3.087	-4.246	-5.63	-5.141	-7.086	-7.26
Operating Margin	-	-1,359.89%	-432.77%	-24,630.14%	-2,171.65%	-9,241.48%	-25,526.23%
Earnings before Tax (EBT)	-	-	-	-	-	-	-
Net income ¹	-7.06	-2.296	-3.237	-4.123	-4.145	-6.803	-6.839
Net margin	-	-1,011.41%	-329.94%	-18,037.62%	-1,750.83%	-8,871.86%	-24,048%
EPS	-0.5000	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-
Announcement Date	9/28/22	10/30/22	4/27/23	9/28/23	10/30/23	5/17/24	5/17/24

¹PLN in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	31.5	-	56.8	51.7	19.8
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow	-	-	-	-	-
ROE (net income / shareholders' equity)	-5.17%	-	-	-	-
ROA (Net income/ Total Assets)	-4.85%	-	-	-	-
Assets ¹	85.85	-	-	-	-
Book Value Per Share ²	5.790	-	9.340	9.400	7.800
Cash Flow per Share	-	-	-	-	-
Capex	0.36	-	44.5	-	-
Capex / Sales	17.88%	-	3,351.13%	-	-
Announcement Date	3/30/20	3/30/23	5/17/24	-	-

¹PLN in Million²PLN

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Molecure S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.78 PLN

Average target price

29.8 PLN

Spread / Average Target

+116.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECURE S.A.	-29.33%	59.06M
VERTEX PHARMACEUTICALS INCORPORATED	+20.95%	127B
REGENERON PHARMACEUTICALS, INC.	+23.00%	116B
ARGENX SE	+25.15%	27.69B
BIONTECH SE	-19.75%	19.62B
GENMAB A/S	-16.57%	16.26B
BEIGENE, LTD.	-16.56%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+11.19%	14.81B
WUXI APPTEC CO., LTD.	-46.65%	14.39B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.11B

Bio Therapeutic Drugs